Sanofi (NASDAQ:SNY) Shares Purchased by OLD National Bancorp IN

OLD National Bancorp IN boosted its position in Sanofi (NASDAQ:SNY) by 5.9% in the fourth quarter, HoldingsChannel.com reports. The firm owned 28,379 shares of the company’s stock after purchasing an additional 1,572 shares during the quarter. OLD National Bancorp IN’s holdings in Sanofi were worth $1,411,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Rise Advisors LLC lifted its position in shares of Sanofi by 98.4% during the 4th quarter. Rise Advisors LLC now owns 506 shares of the company’s stock valued at $25,000 after acquiring an additional 251 shares during the last quarter. Salem Investment Counselors Inc. acquired a new stake in shares of Sanofi during the 4th quarter valued at $27,000. Venturi Wealth Management LLC lifted its position in shares of Sanofi by 163.5% during the 4th quarter. Venturi Wealth Management LLC now owns 535 shares of the company’s stock valued at $27,000 after acquiring an additional 332 shares during the last quarter. Farmers & Merchants Trust Co of Chambersburg PA lifted its position in shares of Sanofi by 115.6% during the 4th quarter. Farmers & Merchants Trust Co of Chambersburg PA now owns 746 shares of the company’s stock valued at $37,000 after acquiring an additional 400 shares during the last quarter. Finally, CNB Bank acquired a new stake in shares of Sanofi during the 3rd quarter valued at $39,000. 10.04% of the stock is currently owned by institutional investors and hedge funds.

Sanofi Trading Up 1.1 %

NASDAQ SNY opened at $47.69 on Wednesday. Sanofi has a 1-year low of $42.63 and a 1-year high of $57.82. The company has a current ratio of 1.27, a quick ratio of 0.87 and a debt-to-equity ratio of 0.19. The company has a market capitalization of $120.64 billion, a PE ratio of 20.21, a price-to-earnings-growth ratio of 1.65 and a beta of 0.61. The firm’s fifty day simple moving average is $47.58 and its 200-day simple moving average is $48.45.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, February 1st. The company reported $0.89 earnings per share for the quarter, missing analysts’ consensus estimates of $0.94 by ($0.05). The company had revenue of $11.76 billion during the quarter, compared to analyst estimates of $13.02 billion. Sanofi had a return on equity of 27.47% and a net margin of 12.56%. As a group, sell-side analysts anticipate that Sanofi will post 4.11 earnings per share for the current fiscal year.

Sanofi Increases Dividend

The firm also recently announced an annual dividend, which will be paid on Thursday, June 6th. Shareholders of record on Friday, May 10th will be given a dividend of $1.478 per share. This represents a yield of 2.98%. This is an increase from Sanofi’s previous annual dividend of $1.38. The ex-dividend date of this dividend is Thursday, May 9th. Sanofi’s dividend payout ratio is presently 58.47%.

Wall Street Analysts Forecast Growth

SNY has been the subject of a number of recent research reports. TheStreet downgraded Sanofi from a “b” rating to a “c” rating in a research report on Friday, February 9th. Morgan Stanley assumed coverage on shares of Sanofi in a research note on Tuesday, January 23rd. They set an “equal weight” rating and a $55.00 target price on the stock. Finally, StockNews.com downgraded shares of Sanofi from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, February 27th. One investment analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the company. Based on data from MarketBeat, Sanofi currently has an average rating of “Hold” and a consensus target price of $55.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.